3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow NKTR-255: new trials by email Literature Review of NKTR-255 trials Research Report on NKTR-255
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-TIL051 in Non-Small Cell Lung Cancer C-TIL051 - Metastatic Non Small Cell Lung Cancer | Phase 1 | Terminated | AbelZeta Inc. | 1 | 2024-02-29 | 2026-01-05 |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Completed | Fred Hutchinson Cancer Center | 27 | 2022-12-08 | 2026-09-21 |
| Study of NKTR 255 in Combination With Cetuximab in Solid Tumors NKTR-255, Cetuximab - Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Nektar Therapeutics | 25 | 2020-10-30 | 2025-06-08 |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255, NKTR-255 Q21, Rituximab - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Nektar Therapeutics | 30 | 2019-10-07 | 2023-06-15 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 56 | 2017-09-01 | 2025-11-18 |
Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm, Residual (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1)
Nektar Therapeutics (2) · AbelZeta Inc. (1) · Fred Hutchinson Cancer Center (1) · Stanford University (1)
United States (5)
Alexandre Hirayama (1) · Lori Muffly, MD, MS (1)
PMID 34001523, PMID 34154392, PMID 34312556, PMID 34515338, PMID 38968138